Roivant Sciences stays a Buy with strong pipeline and $4B cash, but faces regulatory and market risks.

Roivant Sciences Ltd. remains a Buy due to its diversified subsidiaries delivering multiple promising drug candidates and maintaining over $4 billion in cash. Key assets include Immunovant's IMVT-1402 for rheumatoid arthritis, Priovant's LISRAYA for dermatomyositis, and Pulmovant's mosliciguat showing strong Phase 2 results in pulmonary hypertension. Despite these positives, the company faces challenges such as regulatory hurdles, competition, and risks of clinical setbacks. With a $30 billion market cap, investor expectations are high, making risk management crucial going forward.

Roivant Sciences Ltd. is capturing attention as investors weigh its diverse drug pipeline and cash reserves. On Pluang, ROIV shares are priced at USD 42.10, up 2.21% as of Nov 12, 2026 01:41 WIB, reflecting steady interest. The stock carries a market cap near $29.83 billion, with typical investors holding for about 17 days, indicating active trading and engagement with its momentum.